Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NICOLAS M NAMMOUR

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1962426692
CMS profile
133839
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$52,693.48

392 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $32,729.84 78
Biohaven Pharmaceuticals, Inc. $12,902.07 41
Allergan, Inc. $2,264.69 16
Novartis Pharmaceuticals Corporation $358.91 24
Biogen, Inc. $351.25 25
Eisai Inc. $312.47 23
GENZYME CORPORATION $309.62 14
UCB, Inc. $301.09 16
Sunovion Pharmaceuticals Inc. $236.56 12
Alexion Pharmaceuticals, Inc. $229.96 10
ACADIA Pharmaceuticals Inc $222.93 14
Teva Pharmaceuticals USA, Inc. $185.24 8
Genentech USA, Inc. $178.27 9
Adamas Pharmaceuticals, Inc. $171.61 7
Amgen Inc. $166.35 7
Amneal Pharmaceuticals LLC $153.85 9
Kyowa Kirin, Inc. $144.24 6
BOSTON SCIENTIFIC CORPORATION $131.56 6
Neurelis, Inc. $116.34 5
SK Life Science, Inc. $96.83 5
Lilly USA, LLC $91.30 5
Grifols USA, LLC $90.31 3
AstraZeneca Pharmaceuticals LP $88.14 5
CSL Behring $82.48 4
CATALYST PHARMACEUTICALS, INC. $81.08 4
Medtronic, Inc. $67.31 3
Lundbeck LLC $64.38 3
ARBOR PHARMACEUTICALS, INC. $58.25 3
Almatica Pharma LLC $54.51 2
Acorda Therapeutics, Inc $51.92 2
Avanir Pharmaceuticals, Inc. $48.04 3
BANNER LIFE SCIENCES, LLC $47.82 3
EMD Serono, Inc. $45.86 2
Janssen Pharmaceuticals, Inc $37.65 2
Supernus Pharmaceuticals, Inc. $25.43 2
GE HEALTHCARE $24.43 1
Merz Pharmaceuticals, LLC $21.92 1
MITSUBISHI TANABE PHARMA AMERICA, INC. $21.14 1
Nevro Corp. $20.33 1
UPSHER-SMITH LABORATORIES LLC $18.23 1
Alnylam Pharmaceuticals Inc. $17.31 1
LivaNova USA, Inc. $16.53 1
E.R. Squibb & Sons, L.L.C. $15.02 1
Avion Pharmaceuticals $14.98 1
AQUESTIVE THERAPEUTICS, INC. $14.33 1
Neurocrine Biosciences, Inc. $11.10 1

Page 3 of 8; records 101–150 of 392 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NICOLAS M NAMMOUR

NPI 1962426692 · CMS profile ID 133839

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 392 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962426692?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NICOLAS M NAMMOUR, NPI 1962426692, CMS profile ID 133839. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 392 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962426692?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NICOLAS M NAMMOUR, NPI 1962426692, CMS profile ID 133839. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 392 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962426692?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NICOLAS M NAMMOUR, NPI 1962426692, CMS profile ID 133839, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 392 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1962426692?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

392 matching records · $52,693.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 392 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 392.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $24.8709/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843591063 CMS
Avanir Pharmaceuticals, Inc. $13.4909/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801047083 CMS
Genentech USA, Inc. $21.8309/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835958373 CMS
ACADIA Pharmaceuticals Inc $16.8809/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838012753 CMS
Amneal Pharmaceuticals LLC $20.7009/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829670955 CMS
Biohaven Pharmaceuticals, Inc. $13.5309/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852574453 CMS
AbbVie Inc. $18.3209/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282631 CMS
AbbVie Inc. $1,300.0009/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282637 CMS
Eisai Inc. $9.8109/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817990745 CMS
Biogen, Inc. $19.7609/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827851295 CMS
Sunovion Pharmaceuticals Inc. $16.8009/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821760104 CMS
CSL Behring $15.5409/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820182851 CMS
GENZYME CORPORATION $23.0509/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843591061 CMS
AstraZeneca Pharmaceuticals LP $15.7509/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829492007 CMS
Novartis Pharmaceuticals Corporation $17.5909/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110153 CMS
GENZYME CORPORATION $23.6609/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843591057 CMS
AbbVie Inc. $21.6608/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282625 CMS
Biogen, Inc. $11.7908/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827851257 CMS
Biogen, Inc. $4.3208/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827851293 CMS
Biohaven Pharmaceuticals, Inc. $8.2808/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852574451 CMS
Amgen Inc. $37.0708/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825659499 CMS
AbbVie Inc. $7.5708/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282619 CMS
Medtronic, Inc. $25.5108/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827274461 CMS
UCB, Inc. $4.5008/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807390863 CMS
Allergan, Inc. $18.9008/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792885647 CMS
Novartis Pharmaceuticals Corporation $12.9108/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110157 CMS
AbbVie Inc. $3.9008/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282611 CMS
AstraZeneca Pharmaceuticals LP $17.8708/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829457181 CMS
Biogen, Inc. $6.1308/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827851263 CMS
Eisai Inc. $24.9408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817979531 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $21.1408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844025635 CMS
BOSTON SCIENTIFIC CORPORATION $32.1108/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777730261 CMS
ACADIA Pharmaceuticals Inc $22.5408/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838012749 CMS
Allergan, Inc. $4.6508/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792885645 CMS
Adamas Pharmaceuticals, Inc. $24.9508/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834402211 CMS
Biohaven Pharmaceuticals, Inc. $8.5208/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852574449 CMS
Novartis Pharmaceuticals Corporation $14.2108/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813110149 CMS
AbbVie Inc. $10.9108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282605 CMS
Biohaven Pharmaceuticals, Inc. $17.0608/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852574447 CMS
AbbVie Inc. $20.8008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282597 CMS
AbbVie Inc. $1,300.0008/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282584 CMS
AbbVie Inc. $12.3208/04/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282591 CMS
GENZYME CORPORATION $22.3808/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843591041 CMS
Lundbeck LLC $23.0008/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845924985 CMS
Teva Pharmaceuticals USA, Inc. $31.1508/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839709305 CMS
Biogen, Inc. $14.2508/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827851291 CMS
Lilly USA, LLC $18.6908/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 856542245 CMS
Biogen, Inc. $21.0108/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827851289 CMS
Sunovion Pharmaceuticals Inc. $12.8608/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821860995 CMS
AbbVie Inc. $1,300.0007/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795282571 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,697.19 289
PY2020 $17,856.13 279
PY2021 $52,693.48 392
PY2022 $74,150.70 438
PY2023 $36,100.74 401
PY2024 $29,388.53 379
PY2025 $31,331.79 381

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $129,609.35 46
PY2024 Principal investigator $135,530.96 55
PY2023 Recipient $24,868.44 12
PY2023 Principal investigator $119,832.66 38
PY2022 Principal investigator $145,954.34 39
PY2021 Principal investigator $64,859.36 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,250.00 12/24/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228724916
Principal investigator 1 PFIZER INC. $3,826.60 12/24/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228727615
Principal investigator 1 PFIZER INC. $477.00 12/18/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228725820
Principal investigator 1 PFIZER INC. $4,049.28 12/11/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228727457
Principal investigator 1 PFIZER INC. $6,956.14 11/24/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728855
Principal investigator 1 PFIZER INC. $1,440.00 11/20/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728581
Principal investigator 1 PFIZER INC. $500.00 11/13/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728833
Principal investigator 1 PFIZER INC. $500.00 11/13/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228729025
Principal investigator 1 PFIZER INC. $11,950.05 11/06/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728591
Principal investigator 1 PFIZER INC. $2,751.20 11/06/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228728818
Principal investigator 1 PFIZER INC. $1,000.00 10/30/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228737876
Principal investigator 1 PFIZER INC. $1,264.00 10/14/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228736823
Principal investigator 1 PFIZER INC. $500.00 10/09/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228731807
Principal investigator 1 PFIZER INC. $12,272.64 10/09/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228732203
Principal investigator 1 PFIZER INC. $676.00 10/09/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228733500
Principal investigator 1 PFIZER INC. $8,466.40 09/25/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228743187
Principal investigator 1 PFIZER INC. $2,263.85 09/04/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228742574
Principal investigator 1 PFIZER INC. $500.00 09/04/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228742871
Principal investigator 1 PFIZER INC. $500.00 09/04/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228743630
Principal investigator 1 PFIZER INC. $8,384.70 08/27/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228719931
Principal investigator 1 PFIZER INC. $764.00 08/27/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228753780
Principal investigator 1 PFIZER INC. $1,000.00 08/04/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228753442
Principal investigator 1 PFIZER INC. $1,352.00 08/04/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228753596
Principal investigator 1 PFIZER INC. $10,415.04 08/04/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228753890
Principal investigator 1 PFIZER INC. $50.00 06/13/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774096
Principal investigator 1 PFIZER INC. $9,981.89 06/13/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228774637
Principal investigator 1 PFIZER INC. $500.00 06/05/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228775460
Principal investigator 1 PFIZER INC. $1,200.00 05/15/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765314
Principal investigator 1 PFIZER INC. $700.00 05/08/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777102
Principal investigator 1 PFIZER INC. $1,000.00 05/08/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777230
Principal investigator 1 PFIZER INC. $2,714.00 04/24/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777697
Principal investigator 1 PFIZER INC. $1,564.00 04/24/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777705
Principal investigator 1 PFIZER INC. $6,767.04 04/24/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228778026
Principal investigator 1 PFIZER INC. $1,564.00 04/17/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228775843
Principal investigator 1 PFIZER INC. $1,000.00 04/17/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228776163
Principal investigator 1 PFIZER INC. $1,100.00 04/17/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777690
Principal investigator 1 PFIZER INC. $1,713.40 04/04/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228763028
Principal investigator 1 PFIZER INC. $500.00 04/04/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228763417
Principal investigator 1 PFIZER INC. $800.00 04/04/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777695
Principal investigator 1 PFIZER INC. $375.00 03/20/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765682
Principal investigator 1 ABBVIE INC. $5,700.00 02/19/2025 Non-covered Recipient Entity
SCLA MANAGEMENT LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202452514
Principal investigator 1 PFIZER INC. $750.00 02/06/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228768145
Principal investigator 1 PFIZER INC. $500.00 01/23/2025 Non-covered Recipient Entity
SCLA Management LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228766532
Principal investigator 1 PFIZER INC. $2,578.30 01/23/2025 Non-covered Recipient Entity
SCLA Management LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228766815
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $4,292.82 01/18/2025 Non-covered Recipient Entity
NICOLAS M NAMMOUR MD PA DBA NEUROCARE PLUS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335205
Principal investigator 1 ABBVIE INC. $1,200.00 01/16/2025 Non-covered Recipient Entity
SCLA MANAGEMENT LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202439329